Literature DB >> 1968062

Differential processing and turnover of the oncogenically activated neu/erb B2 gene product and its normal cellular counterpart.

S S Huang1, H A Koh, Y Konish, L D Bullock, J S Huang.   

Abstract

In nontransformed DHFR/G-8 cells (NIH 3T3 cells transfected with normal rat neu gene), the normal neu gene product was initially synthesized as a 170-kDa protein bearing endoglycosidase H-sensitive oligosaccharide chains and was then processed to a 175-kDa mature form with endoglycosidase H-resistant, endoglycosidase F-sensitive oligosaccharide chains. Most of this 175-kDa mature form appeared on the cell surface 2 h following synthesis and showed a half-life of approximately 3 h. In the presence of a growth factor(s) partially purified from bovine kidney, the half-life of this 175-kDa normal neu gene product was shortened to less than 30 min. In B104-1-1 cells (NIH 3T3 cells transfected with neu gene activated oncogenically by a point mutation that changes a valine residue to a glutamic acid residue in the putative transmembrane region), the oncogenically activated neu gene product was also synthesized as a 170-kDa precursor with endoglycosidase H-sensitive oligosaccharide chains. However, this 170-kDa precursor diminished very fast and was only partially processed to a 185-kDa mature form which exhibited a half-life of less than 30 min. The 185-kDa activated neu gene product possessed an unidentified post-translational modification in addition to N-linked oligosaccharide chains. Both the precursor and mature forms of the mutationally activated neu gene product showed increased tyrosine-specific phosphorylation as compared with those of their normal counterparts in DHFR/G-8 cells. The mutationally activated neu gene product in B104-1-1 cells shared several features which have been reported previously for the ligand-activated platelet-derived growth factor receptor in v-sis- or c-sis-transformed cells. These properties include: 1) accelerated turnover of the precursor and mature forms compared with the rates of turnover of its normal counterparts, 2) insensitivity of this rapid turnover to lysosomotropic amines, and 3) increased in vivo tyrosine-specific phosphorylation of both the precursor and mature forms. These findings suggest that the mutationally activated neu gene product may transform the cells by mimicking ligand-induced activation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1968062

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Modulatory effect of the transmembrane domain of the protein-tyrosine kinase encoded by oncogene ros: biological function and substrate interaction.

Authors:  C S Zong; L H Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

2.  Characterization of a neu/c-erbB-2 protein-specific activating factor.

Authors:  K Dobashi; J G Davis; Y Mikami; J K Freeman; J Hamuro; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

3.  A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells.

Authors:  G K Scott; R Robles; J W Park; P A Montgomery; J Daniel; W E Holmes; J Lee; G A Keller; W L Li; B M Fendly
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

4.  Molecular kinetics of nerve growth factor receptor trafficking and activation.

Authors:  Jérôme Jullien; Vincent Guili; Louis F Reichardt; Brian B Rudkin
Journal:  J Biol Chem       Date:  2002-06-07       Impact factor: 5.157

5.  Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.

Authors:  Patrick M Glassman; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-07-04       Impact factor: 2.745

6.  17 beta-estradiol mimics ligand activity of the c-erbB2 protooncogene product.

Authors:  S Matsuda; Y Kadowaki; M Ichino; T Akiyama; K Toyoshima; T Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

7.  Analysis of conformational determinants underlying HSP90-kinase interaction.

Authors:  Rama Krishna Kancha; Natalie Bartosch; Justus Duyster
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.